The optimal duration of combined COX and 5-LOX inhibitors to modulate tobacco- and lung cancer-related gene expression in the nasal epithelium as a surrogate for the respiratory epithelium is unknown. This evidence concerns the gene ALOX5 and lung carcinoma.